Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study

Table 2 Number of patient populations

		Number of patients before matching
		VKA	DOAC	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Study population	Stroke	405,437	430,940	53,057	228,609	131,751	14,276
	Embolism	404,823	431,816	52,796	228,522	132,872	14,556
	TIA	405,012	431,574	52,839	228,593	132,547	14,442
	Bleeding	408,402	427,477	53,233	229,934	127,613	13,266
	Mortality	404,695	431,978	52,763	228,499	133,059	14,586
		Number of patients after matching
		VKA	DOAC	Dabigatran*	Rivaroxaban*	Apixaban*	Edoxaban*
Study population	Stroke	347,240	347,240	53,057	228,600	131,748	14,276
	Embolism	347,297	347,297	52,796	228,513	132,869	14,556
	TIA	347,247	347,247	52,839	228,584	132,544	14,442
	Bleeding	346,343	346,343	53,233	229,926	127,610	13,266
	Mortality	347,351	347,351	52,763	228,490	133,056	14,586

VKA vitamin K antagonist, DOAC direct oral anticoagulant, TIA transient ischemic attack
*Number of VKA patients equals number of DOAC patients

ISSN: 1741-7015